Journal of Experimental and Clinical Medicine (Turkey), vol.39, no.2, pp.584-586, 2022 (Scopus)
Dasatinib is one of the second-generation tyrosine kinase inhibitors (TKI) that used as the first line for the treatment of Philadelphia chromosome (Ph) positive chronic myeloid leukemia (CML). Several cardiovascular side effects such as pleural-pericardial effusion, pulmonary hypertension, prolonged QTc interval, and platelet dysfunction have been reported. A 59-year-old female with worsening dyspnoea was diagnosed with cardiac tamponade twice in six months period after initiation of Dasatinib 100 mg per day for CML. She was successfully treated with drainage of effusion percutaneously and discontinuation of Dasatinib. Recurrent cardiac tamponade is a rare complication related to the use of Dasatinib. It should be kept in mind that Dasatinib is a potential agent for pericardial effusion, especially when other possibilities are excluded.